US real-world effectiveness of secukinumab for the treatment of psoriasis: 6-month analysis from the Corrona Psoriasis Registry

Abstract

Objective: To examine the real-world effectiveness of secukinumab with regard to clinical and patientreported outcomes (PROs) from enrollment to a 6-month follow-up visit in patients with psoriasis in the Corrona Psoriasis Registry. Methods: Eligible patients aged ! 18 years who initiated secukinumab at enrollment in the Corrona Psoriasis Registry and had a 6-month follow-up visit (window: 5-9 months) as of December 31 2017, were included in the analysis. Measures of disease severity and PROs were assessed in patients who maintained secukinumab treatment at the 6-month follow-up visit. Results: Of the 144 patients who initiated secukinumab at enrollment and had a 6-month follow-up visit, 118 (81.9%) maintained secukinumab treatment at 6 months and demonstrated significant improvements in affected body surface area (BSA) and 5-point Investigator's Global Assessment (IGA) score (all p < .01). The majority of patients were biologic experienced (89.8%). In addition, patients reported significant improvements in quality of life, as well as in pain, itch, fatigue, work productivity, and daily activities (all p < .01). Conclusions: Secukinumab significantly improved disease severity and PROs after 6 months of follow-up in this real-world study, which is consistent with other current real-world studies.

Secukinumab demonstrates improvements in absolute and relative psoriasis area severity indices in moderate-to-severe plaque psoriasis: results from a European, multicentric, retrospective, real-world study

“…Although secukinumab has been shown to be well tolerated and effective in treating patients with plaque psoriasis and PsA in multiple clinical trials (7-9,29-34) with up to 5-year follow up (35), randomized controlled trials are likely to enroll patient populations with more stringent inclusion/exclusion criteria and generally the study design allows a short-term observation compared to the real-world setting. A variety of real-world studies have been recently published: some of them analyzed secukinumab drug survival (36)(37)(38)(39), whereas others assessed its efficacy in psoriasis patient populations with peculiar features, or assessing its effectiveness as improvement of DLQI, BSA, PGA, and PASI scores (11)(12)(13)(14)(15)(16)(17)(18)(19)(20)(21)(22)(23)(24). Nevertheless, they reported favorable secukinumab safety and effectiveness in terms of mean reduction of PASI value over time, as patient rates achieving PASI 75, PASI 90, and PASI 100 responses at different timepoints, Investigator's Global Assessments or improvements in quality of life measures (11)(12)(13)(14)(15)(16)(17)(18)(19)22).…”

“…Second, the observation period was limited to 52 weeks whereas other studies had longer observational periods (14,15). Third, relatively small cohort of patients was included (17,19,23).…”

“…Recently, some real-world studies describing the effectiveness and safety of secukinumab have been published, but only one study included data on the absolute residual PASI score (11)(12)(13)(14)(15)(16)(17)(18)(19)(20)(21)(22)(23)(24). Indeed, the effectiveness of antipsoriatic treatments is usually reported as the relative 75%, 90%, or 100% improvement from baseline on the Psoriasis Area Severity Index (PASI 75, PASI 90, PASI 100), though there is emerging interest in the evaluation of absolute PASI score reduction as a better benchmark of therapeutic response and the higher clinical relevance of the remaining absolute PASI score as therapeutic target (i.e.…”

Management of Psoriasis With Biologics in Clinical Practice: An Update for 2020

“…Secukinumab therapy displayed notable reduction in symptom severity in this population with difficult-to-treat psoriasis. Its relative success in this cohort provides support for its use in treating patients who have failed other classes of biologics 5.…”

“…One analysis of the Corrona Psoriasis Registry included 144 patients, the majority of whom (89.8%) were biologic experienced, who began secukinumab treatment and returned for a 6-month follow-up (5-9 months). 5 Patients enrolled in the registry were 18 years or older, had been diagnosed with psoriasis by a dermatologist, and initiated or switched an FDAapproved systemic agent or biologic within the last 12 months. Of biologic-experienced participants, 37.7% had used 3 or more biologics.…”